Search Results

There are 4249 results for: content related to: Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

  1. You have free access to this content
    Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

    Alimentary Pharmacology & Therapeutics

    Volume 37, Issue 12, June 2013, Pages: 1172–1183, C. Steenholdt, Y. Palarasah, K. Bendtzen, A. Teisner, J. Brynskov, B. Teisner and C. H. Nielsen

    Version of Record online : 7 MAY 2013, DOI: 10.1111/apt.12330

  2. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF

    Inflammatory Bowel Diseases

    Volume 16, Issue 11, November 2010, Pages: 1898–1904, Akihiro Yamada, Koji Sono, Nobuo Hosoe, Nobuo Takada and Yasuo Suzuki

    Version of Record online : 22 MAR 2010, DOI: 10.1002/ibd.21259

  3. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

    Inflammatory Bowel Diseases

    Volume 18, Issue 9, September 2012, Pages: 1628–1633, Uri Kopylov, Yoav Mazor, Miri Yavzori, Ella Fudim, Lior Katz, Daniel Coscas, Orit Picard, Yehuda Chowers, Rami Eliakim and Shomron Ben-Horin

    Version of Record online : 29 OCT 2011, DOI: 10.1002/ibd.21919

  4. You have free access to this content
    Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 18, Issue 5, May 2012, Pages: 985–1002, Charlotte I. de Bie, Johanna C. Escher and Lissy de Ridder

    Version of Record online : 20 SEP 2011, DOI: 10.1002/ibd.21871

  5. You have free access to this content
    Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

    Alimentary Pharmacology & Therapeutics

    Volume 34, Issue 1, July 2011, Pages: 51–58, C. Steenholdt, M. Svenson, K. Bendtzen, O. Ø. Thomsen, J. Brynskov and M. A. Ainsworth

    Version of Record online : 3 MAY 2011, DOI: 10.1111/j.1365-2036.2011.04682.x

  6. You have free access to this content
    The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 2, January 2011, Pages: 243–250, C. I. De Bie, T. Z. Hummel, A. Kindermann, F. T. M. Kokke, G. M. Damen, C. M. F. Kneepkens, P. F. Van Rheenen, J. J. Schweizer, J. H. Hoekstra, O. F. Norbruis, W. E. Tjon a Ten, A. C. Vreugdenhil, J. M. Deckers-Kocken, C. F. M. Gijsbers, J. C. Escher and L. De Ridder

    Version of Record online : 14 NOV 2010, DOI: 10.1111/j.1365-2036.2010.04507.x

  7. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review

    Inflammatory Bowel Diseases

    Volume 15, Issue 8, August 2009, Pages: 1264–1275, Andrea Cassinotti and Simon Travis

    Version of Record online : 23 FEB 2009, DOI: 10.1002/ibd.20899

  8. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study

    Inflammatory Bowel Diseases

    Volume 17, Issue 10, October 2011, Pages: 2144–2152, Valérie Crombé, Julia Salleron, Guillaume Savoye, Jean-Louis Dupas, Gwénola Vernier-Massouille, Eric Lerebours, Antoine Cortot, Véronique Merle, Francis Vasseur, Dominique Turck, Corinne Gower-Rousseau, Marc Lémann, Jean-Frédéric Colombel and Alain Duhamel

    Version of Record online : 1 FEB 2011, DOI: 10.1002/ibd.21615

  9. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 6, June 2014, Pages: 1177–1185, Michael J Hayes, Adam C Stein and Atsushi Sakuraba

    Version of Record online : 15 MAY 2014, DOI: 10.1111/jgh.12517

  10. You have free access to this content
    Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels

    Clinical & Experimental Immunology

    Volume 172, Issue 1, April 2013, Pages: 54–62, L. Semerano, J. Biton, L. Delavallée, E. Duvallet, E. Assier, N. Bessis, E. Bernier, O. Dhellin, G. Grouard-Vogel and M.-C. Boissier

    Version of Record online : 10 MAR 2013, DOI: 10.1111/cei.12040

  11. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease

    Inflammatory Bowel Diseases

    Volume 15, Issue 9, September 2009, Pages: 1295–1301, Fabian Schnitzler, Herma Fidder, Marc Ferrante, Maja Noman, Ingrid Arijs, Gert Van Assche, Ilse Hoffman, Kristel Van Steen, Séverine Vermeire and Paul Rutgeerts

    Version of Record online : 1 APR 2009, DOI: 10.1002/ibd.20927

  12. Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)

    Inflammatory Bowel Diseases

    Volume 18, Issue 11, November 2012, Pages: 2043–2055, Daniel A. Sussman, Nisa Kubiliun, Parvez M. Mulani, Jingdong Chao, Carol A.T. Gillis, Mei Yang, Mei Lu and Maria T. Abreu

    Version of Record online : 12 JAN 2012, DOI: 10.1002/ibd.22873

  13. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus

    Journal of Gastroenterology and Hepatology

    Volume 25, Issue 5, May 2010, Pages: 886–891, Shuji Yamamoto, Hiroshi Nakase, Minoru Matsuura, Yusuke Honzawa, Satohiro Masuda, Ken-ichi Inui and Tsutomu Chiba

    Version of Record online : 7 DEC 2009, DOI: 10.1111/j.1440-1746.2009.06206.x

  14. You have free access to this content
    Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 36, Issue 7, October 2012, Pages: 650–659, C. Steenholdt, C. Enevold, M. A. Ainsworth, J. Brynskov, O. Ø. Thomsen and K. Bendtzen

    Version of Record online : 5 AUG 2012, DOI: 10.1111/apt.12010

  15. You have free access to this content
    eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 36, Issue 9, November 2012, Pages: 840–849, N. Pedersen, M. Elkjaer, D. Duricova, J. Burisch, C. Dobrzanski, N. N. Andersen, T. Jess, F. Bendtsen, E. Langholz, S. Leotta, T. Knudsen, N. Thorsgaard and P. Munkholm

    Version of Record online : 12 SEP 2012, DOI: 10.1111/apt.12043

  16. Gastroenterologists' prescribing of infliximab for Crohn's disease: A national survey

    Inflammatory Bowel Diseases

    Volume 15, Issue 10, October 2009, Pages: 1467–1475, Meaghan St. Charles, Sheila R. Weiss Smith, Robert Beardsley, Donald O. Fedder, Olivia Carter-Pokras and Raymond K. Cross

    Version of Record online : 5 MAR 2009, DOI: 10.1002/ibd.20904

  17. You have free access to this content
    High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 9, May 2011, Pages: 1053–1058, Z. Zelinkova, C. de Haar, L. de Ridder, M. J. Pierik, E. J. Kuipers, M. P. Peppelenbosch and C. J. van der Woude

    Version of Record online : 1 MAR 2011, DOI: 10.1111/j.1365-2036.2011.04617.x

  18. Efficacy and safety of infliximab in treating patients with ulcerative colitis: Experiences from a single medical center in southern China

    Journal of Digestive Diseases

    Volume 15, Issue 9, September 2014, Pages: 483–490, You Lian Zhou, Shan Xie, Pu Wang, Ting Zhang, Min Yi Lin, Jia Sheng Tan, Fa Chao Zhi, Bo Jiang and Ye Chen

    Version of Record online : 1 SEP 2014, DOI: 10.1111/1751-2980.12161

  19. You have free access to this content
    Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 4, August 2014, Pages: 338–353, B. Pariente and D. Laharie

    Version of Record online : 23 JUN 2014, DOI: 10.1111/apt.12838

  20. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3-year prospective randomized open trial

    Inflammatory Bowel Diseases

    Volume 18, Issue 9, September 2012, Pages: 1617–1623, Koji Yoshida, Ken Fukunaga, Hiroki Ikeuchi, Koji Kamikozuru, Nobuyuki Hida, Yoshio Ohda, Yoko Yokoyama, Masaki Iimuro, Naohisa Takeda, Kyoichi Kato, Risa Kikuyama, Kazuko Nagase, Kazutoshi Hori, Shiro Nakamura, Hiroto Miwa and Takayuki Matsumoto

    Version of Record online : 13 NOV 2011, DOI: 10.1002/ibd.21928